{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Report Scoring\n",
    "\n",
    "This notebook is used to score and evaluate target genes for specific diseases **after the report is generated**. \n",
    "\n",
    "The report scoring consists of two steps:\n",
    "\n",
    "1. Scoring the candidate gene for the specific disease\n",
    "2. Save the scoring results as a CSV file\n",
    "\n",
    "It utilizes 13 AgentScorers to score a candidate gene for a specific disease. The 13 scoring criteria of 4 sections are as follows:\n",
    "\n",
    "**Category 1: Causal Inference**\n",
    "\n",
    "    - Genetic Evidence\n",
    "    - Differential Expression\n",
    "    - Mechanism of Action\n",
    "    - In Vitro/In Vivo Experiments\n",
    "\n",
    "**Category 2: Tractability**    \n",
    "\n",
    "    - Small Molecule Tractability\n",
    "    - Antibody Tractability\n",
    "    - siRNA Tractability\n",
    "\n",
    "**Category 3: Competitiveness**\n",
    "\n",
    "    - Small Molecule Competitiveness\n",
    "    - Antibody/siRNA Competitiveness\n",
    "    - Unmet Medical Needs\n",
    "\n",
    "**Category 4: Doability**\n",
    "\n",
    "    - Experimental Model Availability (Assayability)\n",
    "    - Biomarker Availability\n",
    "    - Safety\n",
    "\n",
    "The scoring helps quantify and compare the potential of different gene targets for therapeutic development."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Scoring the candidate gene for the specific disease\n",
    "\n",
    "This step scores the candidate gene for the specific disease."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from Target_Scoring_AgentScorer.tools import *\n",
    "from Target_Scoring_AgentScorer.scoring_sections import *\n",
    "from Report_Generation_AgentAnalyst.tools import get_gene_list, get_gene_full_name\n",
    "from config import setup_api_keys"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "setup_api_keys()\n",
    "llm = testChat() # initialize the LLM"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Input Portal\n",
    "\n",
    "You need to provide the following information to generate a specific section of gene analysis reports:\n",
    "\n",
    "1. gene_list: a list of genes\n",
    "2. disease_name: the name of the disease\n",
    "3. section_name: the name of the section you want to generate\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# set the disease name\n",
    "disease_name = 'atherosclerosis'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# set the gene list, please provide in the form of short gene code\n",
    "gene_list = ['PCSK9'] "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['PCSK9_proprotein_convertase_subtilisin_kexin_type_9']\n"
     ]
    }
   ],
   "source": [
    "from Report_Generation_AgentAnalyst.run_section import directory_set_up\n",
    "#get current directory\n",
    "prefix = directory_set_up() + '/'\n",
    "\n",
    "'''\n",
    "# if you want to generate reports for the five diseases mentioned in the paper\n",
    "# 'atherosclerosis', 'non_small_cell_lung_cancer', 'rheumatoid_arthritis', 'type2_diabetes', and 'inflammatory_bowel_disease'\n",
    "# you can use the following code to get the corresponding gene list\n",
    "\n",
    "disease_name = 'non_small_cell_lung_cancer'\n",
    "\n",
    "# get the gene list\n",
    "gene_list = get_gene_list(disease_name, prefix=prefix)\n",
    "'''\n",
    "\n",
    "# get the full gene name\n",
    "gene_list = [gene + '_' + get_gene_full_name(gene).replace(' ', '_').replace('/', '_').lower() for gene in gene_list]\n",
    "print(gene_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "preferred_moa = ''\n",
    "match_moa = False"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Run the scoring functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "report_pcsk9_all.mdreport_pcsk9_all.md\n",
      "\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "--------report chunk----------\n",
      "\n",
      "### human_tissue_distribution\n",
      "| Tissue Type | Expression Value |\n",
      "|-------------|------------------|\n",
      "| liver | 47.6 |\n",
      "| cerebellum | 10.1 |\n",
      "| lung | 7.6 |\n",
      "| esophagus | 5.3 |\n",
      "| pancreas | 5.2 |\n",
      "| colon | 4.4 |\n",
      "| small intestine | 3.3 |\n",
      "| duodenum | 3.0 |\n",
      "| rectum | 1.5 |\n",
      "| vagina | 1.5 |\n",
      "| stomach | 1.3 |\n",
      "| skin | 1.3 |\n",
      "| cervix | 1.0 |\n",
      "| smooth muscle | 0.7 |\n",
      "| appendix | 0.7 |\n",
      "| testis | 0.4 |\n",
      "| bone marrow | 0.4 |\n",
      "| fallopian tube | 0.4 |\n",
      "| salivary gland | 0.4 |\n",
      "| spleen | 0.3 |\n",
      "| tonsil | 0.3 |\n",
      "| urinary bladder | 0.3 |\n",
      "| adipose tissue | 0.3 |\n",
      "| endometrium | 0.3 |\n",
      "| epididymis | 0.3 |\n",
      "| seminal vesicle | 0.2 |\n",
      "| adrenal gland | 0.2 |\n",
      "| basal ganglia | 0.2 |\n",
      "| parathyroid gland | 0.2 |\n",
      "| spinal cord | 0.2 |\n",
      "| kidney | 0.1 |\n",
      "| breast | 0.1 |\n",
      "| cerebral cortex | 0.1 |\n",
      "| gallbladder | 0.1 |\n",
      "| midbrain | 0.1 |\n",
      "| pituitary gland | 0.1 |\n",
      "| hypothalamus | 0.1 |\n",
      "| ovary | 0.1 |\n",
      "| heart muscle | 0.0 |\n",
      "| lymph node | 0.0 |\n",
      "| retina | 0.0 |\n",
      "| hippocampal formation | 0.0 |\n",
      "| prostate | 0.0 |\n",
      "| placenta | 0.0 |\n",
      "| choroid plexus | 0.0 |\n",
      "| thymus | 0.0 |\n",
      "| thyroid gland | 0.0 |\n",
      "| tongue | 0.0 |\n",
      "| amygdala | 0.0 |\n",
      "| skeletal muscle | 0.0 |\n",
      "\n",
      "### Rationale:\n",
      "1. **Tissue Specificity of PCSK9**:\n",
      "   - **Liver**: The highest expression of PCSK9 is in the liver. It plays a crucial role in regulating lipid metabolism by degrading low-density lipoprotein receptors (LDLR) and hence has a significant impact on plasma cholesterol levels. This is supported by evidence that \"The regulation of LDLR by PCSK9 displayed tissue specificity, with liver being the most responsive tissue\" [1].\n",
      "   - **Other tissues**: PCSK9 shows a medium level of expression in multiple tissues, including the cerebellum, lung, esophagus, pancreas, and colon. According to the Human Protein Atlas, \"Even though the PCSK9 transgene was highly expressed in kidney, LDLR proteins were suppressed to a lower extent in this tissue than in liver\" [2].\n",
      "   - Summary: The highest expression of PCSK9 is observed in the liver, which aligns with its primary role in cholesterol metabolism. Meanwhile, its expression levels in other tissues are non-negligible but considerably lower.\n",
      "\n",
      "2. **Differential Expression During Atherosclerosis Progression**:\n",
      "   - Direct evidence indicates that PCSK9 is upregulated in response to inflammatory stimuli and is involved in the progression of atherosclerosis. Specifically, PCSK9 treatment increased VLA-4 expression and its mRNA expression was induced by pro-inflammatory cytokines [3].\n",
      "   - Studies show that targeted interventions, such as the use of novel AAV vectors to silence hepatic PCSK9, can mitigate the progression of atherosclerosis, indicating that PCSK9 expression changes in response to disease conditions [4][5].\n",
      "\n",
      "### Conclusion:\n",
      "- **Tissue Specificity**: PCSK9 exhibits its highest expression in the liver, which is critical for its function in cholesterol regulation. There is medium-level ubiquitous expression across other tissues.\n",
      "- **Differential Expression during Atherosclerosis**: There is strong direct evidence that PCSK9 is differentially expressed during the progression of atherosclerosis, with significant changes in expression levels in response to inflammatory stimuli and disease progression.\n",
      "\n",
      "### References:\n",
      "1. URL: https://pubmed.ncbi.nlm.nih.gov/19060325/\n",
      "   Quoted sentence: \"The regulation of LDLR by PCSK9 displayed tissue specificity, with liver being the most responsive tissue.\"\n",
      "2. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2724049/\n",
      "   Quoted sentence: \"Even though the PCSK9 transgene was highly expressed in kidney, LDLR proteins were suppressed to a lower extent in this tissue than in liver.\"\n",
      "3. URL: https://www.nature.com/articles/s41467-024-46336-2\n",
      "   Quoted sentence: \"PCSK9 treatment increased VLA-4 expression in THP-1 ... e PCSK9 mRNA expression induced by pro-inflammatory cytokines was analyzed by qPCR.\"\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S2329050124002067\n",
      "   Quoted sentence: \"... PCSK9 expression and thereby prevent and mitigate the progression of atherosclerosis.\"\n",
      "5. URL: https://pubmed.ncbi.nlm.nih.gov/39897642/\n",
      "   Quoted sentence: \"... regulation and atherosclerosis progression. Here, we developed a ... Keywords: adeno-associated virus; atherosclerosis; gene therapy; inflammation.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|                         | strong - positive (+1)                             | Weak - positive (+0.5)                          | neutral (0)                        | Weak negative (-0.5)                      | Strong negative (-1)                                    |\n",
      "|-------------------------|----------------------------------------------------|-------------------------------------------------|------------------------------------|--------------------------------------------|--------------------------------------------------------|\n",
      "| Differential expression | Target gene differentially expressed during disease progression | Target gene specifically expressed in disease associated tissue and not expressed much in other tissues. If it is also expressed much in many other tissues, then it is not positive. | The expression pattern of the target gene is not clear | Target gene is ubiquitously expressed | Target gene not expressed in the intent to target tissue |\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **differential expression of pcsk9**.\n",
      "\n",
      "Please use the table above to **rate the level of differential expression based on a report user provided.** Each column represents a different level of differential expression, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "- **If the target gene is differentially expressed during disease progression, it is a strong positive sign.**. IGNORE all other factors in this case.\n",
      "- If the gene is **predominantly expressed** in the tissue associated with the disease (or significantly higher in relevant tissues, even if moderately expressed in others), it is a **weak positive indicator**.\n",
      "- If the gene is **ubiquitously expressed**, it is a **weak negative indicator**.\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Gene Expression | Rationale of Rating | Rating |\n",
      "|-----------------|---------------------|--------|\n",
      "| Is it differentially expressed during disease progression (this is a strong positive sign)?/Is pcsk9 specifically differentially expressed in the disease tissue (this is a weak positive sign)?/ Is pcsk9 expression pattern of the target gene is not clear (this is a neutral sign)? /Is pcsk9 ubiquitously expressed (this is a weak negative sign)?/ If pcsk9 is not expressed in the disease tissue, it is a strong negative sign. | Illustrate why you give this rating | After evaluating the content, select a category from the following options: [Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]. **Only put the category and say nothing else** |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "--------report chunk----------\n",
      "\n",
      "### competitive_edge\n",
      "Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.\n",
      "\n",
      "### Small Molecules\n",
      "\n",
      "| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |\n",
      "| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |\n",
      "| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |\n",
      "\n",
      "### Antibodies\n",
      "\n",
      "| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "\n",
      "### siRNA\n",
      "\n",
      "| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |\n",
      "| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |\n",
      "\n",
      "### Rationale\n",
      "The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.\n",
      "\n",
      "### Conclusion\n",
      "Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:\n",
      "- **Small molecules:** Phase 2b (MK-0616)\n",
      "- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)\n",
      "- **siRNA:** Phase 3 (Inclisiran)\n",
      "\n",
      "### References\n",
      "1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: \"AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.\"\n",
      "\n",
      "2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/\n",
      "   Quoted sentence: \"MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study.\"\n",
      "\n",
      "3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx\n",
      "   Quoted sentence: \"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research.\"\n",
      "\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080\n",
      "   Quoted sentence: \"Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events.\"\n",
      "\n",
      "5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/\n",
      "   Quoted sentence: \"The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials.\"\n",
      "\n",
      "6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/\n",
      "   Quoted sentence: \"Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials.\"\n",
      "\n",
      "7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full\n",
      "   Quoted sentence: \"Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes.\"\n",
      "\n",
      "8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions\n",
      "   Quoted sentence: \"Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|                        | strong - positive (+1)               | Weak - positive (+0.5)          | neutral (0)                       | Weak negative (-0.5)                    | Strong negative (-1)                        |\n",
      "|------------------------|--------------------------------------|---------------------------------|----------------------------------|------------------------------------------|---------------------------------------------|\n",
      "|                        | No reported drug development activity for **antibodies or sirna**| There are pre-clinical development activities for **antibodies or sirna**| There are early clinical development activities (**phase 1, phase 2**) for **antibodies or sirna**| There are pipelines in late stage clinical (**phase 3**) for **antibodies or sirna**| **Approved for antibodies or sirna drugs** for the same target for the same indication|\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **competitiveness of the pcsk9 in the antibody or sirna drug market**.\n",
      "\n",
      "Please use the table above to **rate the level of competitiveness of pcsk9 based on a report user provided.** Each column represents a different level of competitiveness of pcsk9, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Drug Development Pipelines Information | Rating | Rationale of Rating |\n",
      "|----------------------------------------|--------|---------------------|\n",
      "| Are there drug development activities and pipelines of pcsk9 for atherosclerosis? (Only consider those pipelines for atherosclerosis) | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "--------report chunk----------\n",
      "\n",
      "### competitive_edge\n",
      "Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.\n",
      "\n",
      "### Small Molecules\n",
      "\n",
      "| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |\n",
      "| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |\n",
      "| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |\n",
      "\n",
      "### Antibodies\n",
      "\n",
      "| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "\n",
      "### siRNA\n",
      "\n",
      "| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |\n",
      "| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |\n",
      "\n",
      "### Rationale\n",
      "The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.\n",
      "\n",
      "### Conclusion\n",
      "Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:\n",
      "- **Small molecules:** Phase 2b (MK-0616)\n",
      "- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)\n",
      "- **siRNA:** Phase 3 (Inclisiran)\n",
      "\n",
      "### References\n",
      "1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: \"AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.\"\n",
      "\n",
      "2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/\n",
      "   Quoted sentence: \"MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study.\"\n",
      "\n",
      "3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx\n",
      "   Quoted sentence: \"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research.\"\n",
      "\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080\n",
      "   Quoted sentence: \"Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events.\"\n",
      "\n",
      "5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/\n",
      "   Quoted sentence: \"The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials.\"\n",
      "\n",
      "6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/\n",
      "   Quoted sentence: \"Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials.\"\n",
      "\n",
      "7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full\n",
      "   Quoted sentence: \"Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes.\"\n",
      "\n",
      "8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions\n",
      "   Quoted sentence: \"Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "| Unmet Needs | Strong Positive (+1) | Weak Positive (+0.5) | Neutral (0) | Weak Negative (-0.5) | Strong Negative (-1) |\n",
      "| --- | --- | --- | --- | --- | --- |\n",
      "|  | Large patient population or estimated drug market >1billion for the disease & No approved drugs for the target gene | Large Market for the disease & there are approved drugs but patients prefer less frequent dosing, oral format or reduced side effect (i.e., better drugs) for the target gene. | Medium Market Size (<1billion USD/year) for the disease & No approved drugs for the target gene.  | Medium Market Size for the disease and there are approved drugs but patients prefer less frequent dosing or oral format or reduced side effect (i.e., better drugs) for the target gene 2. Small market size for the disease & No approved Drugs for the target gene | Only need to meet one of the following requirements 1. Small market size for the disease 2. Patients are happy with current drugs for the target gene.|\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **unmet need of the pcsk9**.\n",
      "\n",
      "Please use the table above to **rate the level of \n",
      "| Unmet Need | Rating | Rationale of Rating |\n",
      "|------------|--------|---------------------|\n",
      "| | After evaluating the content, you **can only select a category from the following options [Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)] Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      " based on a report user provided.** Each column represents a different level of \n",
      "| Unmet Need | Rating | Rationale of Rating |\n",
      "|------------|--------|---------------------|\n",
      "| | After evaluating the content, you **can only select a category from the following options [Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)] Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      ", from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "Think about following questions before doing rating.\n",
      "- Is there a large patient population or estimated drug market >1 billion for atherosclerosis? \n",
      "- Is there no drug available for pcsk9? \n",
      "- Are there approved drugs for pcsk9? \n",
      "- Do patients prefer less frequent dosing drugs for pcsk9? If yes, there is unmet need.\n",
      "- Do patients prefer oral format drugs for pcsk9? If yes, there is unmet need.\n",
      "- Do patients prefer reduced side effect drugs for pcsk9? If yes, there is unmet need.\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "--------report chunk----------\n",
      "\n",
      "### competitive_edge\n",
      "Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.\n",
      "\n",
      "### Small Molecules\n",
      "\n",
      "| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |\n",
      "| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |\n",
      "| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |\n",
      "\n",
      "### Antibodies\n",
      "\n",
      "| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "\n",
      "### siRNA\n",
      "\n",
      "| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |\n",
      "| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |\n",
      "\n",
      "### Rationale\n",
      "The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.\n",
      "\n",
      "### Conclusion\n",
      "Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:\n",
      "- **Small molecules:** Phase 2b (MK-0616)\n",
      "- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)\n",
      "- **siRNA:** Phase 3 (Inclisiran)\n",
      "\n",
      "### References\n",
      "1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: \"AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.\"\n",
      "\n",
      "2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/\n",
      "   Quoted sentence: \"MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study.\"\n",
      "\n",
      "3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx\n",
      "   Quoted sentence: \"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research.\"\n",
      "\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080\n",
      "   Quoted sentence: \"Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events.\"\n",
      "\n",
      "5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/\n",
      "   Quoted sentence: \"The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials.\"\n",
      "\n",
      "6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/\n",
      "   Quoted sentence: \"Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials.\"\n",
      "\n",
      "7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full\n",
      "   Quoted sentence: \"Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes.\"\n",
      "\n",
      "8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions\n",
      "   Quoted sentence: \"Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|                        | strong - positive (+1)               | Weak - positive (+0.5)          | neutral (0)                       | Weak negative (-0.5)                    | Strong negative (-1)                        |\n",
      "|------------------------|--------------------------------------|---------------------------------|----------------------------------|------------------------------------------|---------------------------------------------|\n",
      "|                        | No reported drug development activity for pcsk9 **small molecule** drugs in atherosclerosis| There are pre-clinical development activities for pcsk9 **small molecules** drugs in atherosclerosis| There are early clinical development activities (**phase 1, phase 2**) for pcsk9 **small molecule** drugs in atherosclerosis| There are pipelines in late stage clinical (**phase 3**) for pcsk9 **small molecules** in atherosclerosis| **There are approved pcsk9 small molecule drugs** in atherosclerosis|\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **competitiveness of the pcsk9 in the small molecules drug market**.\n",
      "\n",
      "Please use the table above to **rate the level of competitiveness of pcsk9 based on a report user provided.** Each column represents a different level of competitiveness of pcsk9, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "- NOTE: CHECK the \"targeted protein\" columns in competitive edge report tables to check if the pipelines is for pcsk9. If not, you need to IGNORE the pipeline.\n",
      "- Think about the clinical phases of the existing small molecule drugs **directly** targeting the pcsk9 in **atherosclerosis**. If it is not directly targeted, then it is not considered. \n",
      "- Phase 1 and 2 leads to **Netural (0)** rating.\n",
      "- Phase 3 leads to **Weak negative (+0.5)** rating.\n",
      "- Approved leads to **Strong negative (-1)** rating.\n",
      "- If there are only preclinical development activties, it leads to **Weak positive (+0.5)** rating.\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Drug Development Pipelines Information | Rating | Rationale of Rating |\n",
      "|----------------------------------------|--------|---------------------|\n",
      "| Are there drug development activities and pipelines of pcsk9 for atherosclerosis? (Only consider those pipelines for atherosclerosis) | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "--------report chunk----------\n",
      "Druggability Report:\n",
      "\n",
      "### druggability\n",
      "### Collected Information on PCSK9\n",
      "\n",
      "| Gene name | Subcellular distribution | Tissue specific expression | Protein structure available? | Membrane protein | Ligand binder | Small molecule binder | Pocket | Small Molecule Tool Compound | Reference |\n",
      "|-----------|--------------------------|----------------------------|------------------------------|------------------|---------------|-----------------------|--------|------------------------------|-----------|\n",
      "| PCSK9     | Secreted protein           | Highly expressed in liver, detected in multiple tissues | Yes, crystal structure available (2.3 A)  |  No             | Yes           | Yes                   | Yes    | Compound 16, E28362, AZD0780 | [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]  |\n",
      "\n",
      "#### Detailed Analysis:\n",
      "\n",
      "1. **Gene Name**: PCSK9\n",
      "\n",
      "2. **Subcellular Distribution**:\n",
      "   - PCSK9 is primarily a secreted protein that acts extracellularly to regulate LDL receptor levels.\n",
      "\n",
      "3. **Tissue and Cell Type Specific Expression**:\n",
      "   - PCSK9 is highly expressed in the liver, but it is also detected in other tissues such as the intestine, kidneys, and central nervous system. This wide tissue distribution facilitates its systemic effects on cholesterol homeostasis.\n",
      "\n",
      "4. **Protein Structure**:\n",
      "   - The crystal structure of PCSK9 is available at 2.3 Å resolution. Detailed structural information allows precise targeting via small-molecule inhibitors or biologics.\n",
      "\n",
      "5. **Membrane Protein**:\n",
      "   - PCSK9 is not a membrane-bound protein itself but interacts with membrane receptors such as the LDL receptor, which is crucial for its function.\n",
      "\n",
      "6. **Ligand Binder**:\n",
      "   - PCSK9 binds to ligands, including its primary interaction partner, the LDL receptor, making it a feasible target for ligand-based inhibition strategies.\n",
      "\n",
      "7. **Small Molecule Binder**:\n",
      "   - Evidence shows that PCSK9 can bind small molecules in its receptor-binding domains. Small molecule inhibitors of PCSK9 have been explored, with some advancing to clinical studies.\n",
      "\n",
      "8. **Pocket**:\n",
      "   - Structural studies have identified binding pockets on PCSK9, including the LDL receptor interaction interface, supporting the development of compounds targeting these pockets.\n",
      "\n",
      "9. **Small Molecule Tool Compounds**:\n",
      "   - Several small molecule tool compounds, such as Compound 16, E28362, and AZD0780, have been identified. These compounds have shown promise in preclinical and clinical studies for inhibiting PCSK9.\n",
      "\n",
      "### Rationale for Suitable Modalities\n",
      "\n",
      "1. **Biologics (Monoclonal Antibodies)**:\n",
      "   - Targeting PCSK9 with monoclonal antibodies has been highly effective. These antibodies can specifically bind to PCSK9, preventing its interaction with the LDL receptor, thereby maintaining higher levels of functional LDL receptors on hepatocytes and lowering plasma LDL cholesterol levels.\n",
      "   - **Example**: Evolocumab, Alirocumab.\n",
      "\n",
      "2. **Small Molecule Inhibitors**:\n",
      "   - Small molecule inhibitors can bind to specific sites on PCSK9, blocking its interaction with the LDL receptor or promoting its degradation. The availability of its crystal structure facilitates the design of such molecules.\n",
      "   - **Examples**: Compounds such as Compound 16, E28362, and AZD0780 are in advanced stages of development.\n",
      "\n",
      "3. **Gene Therapy**:\n",
      "   - Gene editing technologies like CRISPR can be used to knock out or modify the PCSK9 gene to reduce its expression, providing a potentially long-term solution for patients with hypercholesterolemia.\n",
      "\n",
      "4. **RNA-based Therapies**:\n",
      "   - Antisense oligonucleotides or small interfering RNA (siRNA) targeting PCSK9 mRNA can reduce the production of PCSK9 in the liver, thereby decreasing its activity.\n",
      "   - **Example**: Inclisiran.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "Given its significant role in cholesterol metabolism and its well-characterized interaction with the LDL receptor, PCSK9 is druggable via multiple modalities:\n",
      "\n",
      "- **Biologics (Monoclonal antibodies)** and **Small Molecule Inhibitors** are the most promising and feasible approaches due to their ability to effectively inhibit the PCSK9-LDL receptor interaction, as evidenced by numerous clinical successes and available tool compounds.\n",
      "- **RNA-based therapies** and **Gene Therapy** offer innovative approaches for long-term regulation of PCSK9 levels and activity but require further development and testing.\n",
      "\n",
      "### References\n",
      "\n",
      "1. URL: https://pubmed.ncbi.nlm.nih.gov/26323289/\n",
      "   Quoted sentence: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.\n",
      "\n",
      "2. URL: https://www.proteinatlas.org/ENSG00000169174-PCSK9/tissue\n",
      "   Quoted sentence: PCSK9 is highly expressed in liver, detected in multiple tissues.\n",
      "\n",
      "3. URL: https://academic.oup.com/edrv/article/43/3/558/6385885\n",
      "   Quoted sentence: Here we report the crystal structure of human PCSK9 at 2.3 A resolution.\n",
      "\n",
      "4. URL: https://www.ncbi.nlm.nih.gov/gene/100102\n",
      "   Quoted sentence: PCSK9 belongs to the proteinase K family of subtilases, and its catalytic domain exhibits 25% of protein sequence identity to that of its closest family member.\n",
      "\n",
      "5. URL: https://pubs.acs.org/doi/10.1021/jacs.7b09360\n",
      "   Quoted sentence: This paper describes how side-chain orientations in preferred conformations of carefully designed chemotypes were compared with LDLR side chains at the PCSK9 interaction site.\n",
      "\n",
      "6. URL: https://www.nature.com/articles/s41401-024-01305-9\n",
      "   Quoted sentence: E28362 can block the interaction between PCSK9 and LDLR, induce the degradation of PCSK9, increase LDLR protein levels, and alleviate hyperlipidemia.\n",
      "\n",
      "7. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: Positive results from a Phase I trial of AZD0780, an oral small molecule PCSK9 inhibitor administered on top of statin treatment, were presented.\n",
      "\n",
      "8. URL: https://www.sciencedirect.com/science/article/pii/S2451945619303228\n",
      "   Quoted sentence: Analysis of the binding interface between the two proteins sheds light on the difficulty in identifying small-molecule ligands for PCSK9.\n",
      "\n",
      "9. URL: https://www.mdpi.com/2227-9059/12/2/286\n",
      "   Quoted sentence: PCSK9 inhibitors, also referred to as PCSK9i, are highly potent medications for reducing LDL-C levels, significantly enhancing our capacity to manage hypercholesterolemia.\n",
      "\n",
      "10. URL: https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202400208\n",
      "   Quoted sentence: Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9.\n",
      "\n",
      "\n",
      "------------------\n",
      "Competitive Edge Report:\n",
      "\n",
      "### competitive_edge\n",
      "Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.\n",
      "\n",
      "### Small Molecules\n",
      "\n",
      "| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |\n",
      "| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |\n",
      "| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |\n",
      "\n",
      "### Antibodies\n",
      "\n",
      "| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "\n",
      "### siRNA\n",
      "\n",
      "| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |\n",
      "| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |\n",
      "\n",
      "### Rationale\n",
      "The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.\n",
      "\n",
      "### Conclusion\n",
      "Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:\n",
      "- **Small molecules:** Phase 2b (MK-0616)\n",
      "- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)\n",
      "- **siRNA:** Phase 3 (Inclisiran)\n",
      "\n",
      "### References\n",
      "1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: \"AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.\"\n",
      "\n",
      "2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/\n",
      "   Quoted sentence: \"MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study.\"\n",
      "\n",
      "3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx\n",
      "   Quoted sentence: \"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research.\"\n",
      "\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080\n",
      "   Quoted sentence: \"Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events.\"\n",
      "\n",
      "5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/\n",
      "   Quoted sentence: \"The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials.\"\n",
      "\n",
      "6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/\n",
      "   Quoted sentence: \"Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials.\"\n",
      "\n",
      "7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full\n",
      "   Quoted sentence: \"Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes.\"\n",
      "\n",
      "8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions\n",
      "   Quoted sentence: \"Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|     | strong - positive (+1)                           | Weak - positive (+0.5)                       | neutral (0)                         | Weak negative (-0.5)                     | Strong negative (-1)               |\n",
      "|-----|--------------------------------------------------|---------------------------------------------|-------------------------------------|------------------------------------------|-------------------------------------|\n",
      "|   | Small molecule drugs in clinical trials or on the market | **Both Target Crystal structure and Tool compound small molecule** available | Target Crystal structure available | No obvious binding pocket for the target | No structure, no tool compound     |\n",
      "| Small molecules |\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **suitability of small molecules targeting the pcsk9**.\n",
      "\n",
      "Please use the table above to **rate the level of suitability of small molecule for pcsk9 based on a report user provided.** Each column represents a different level of suitability of small molecule for pcsk9, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "- If there are small molecule drugs in clinical trial or being approved for pcsk9,, it **means the target is strong positive (+1)**.\n",
      "- If **crystal structures and tool compounds** (have to have both) for pcsk9 are available, it **means the target is weak positive (+0.5)**.\n",
      "- If only crystal structures are available for pcsk9,, it **means the target is neutral (0)**.\n",
      "- If only obvious pocket site is available for pcsk9, it **means the target is weak negative (-0.5)**.\n",
      "- If none of the structure and tool compounds are available for pcsk9, it **means the target is strong negative (-1)**.\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Data Availability | Rating | Rationale of Rating |\n",
      "|-------------------|--------|---------------------|\n",
      "| - Are there any existing small molecule drugs on pcsk9? - Are crystal structures available? (If yes, then if there is an obvious pocket site?) - Are there tool compounds for pcsk9? | After evaluating the content, select a category from the following options:<br>[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]. **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "report_pcsk9_all.md\n",
      "report_pcsk9_all.md\n",
      "--------report chunk----------\n",
      "\n",
      "### assays\n",
      "### ------------In vitro and In vivo Experimental Assay Design---------\n",
      "\n",
      "| Gene name | Experimental assay | Cell or animal model can be used | Tool compound | Disease relevant readout | Reference |\n",
      "|-----------|--------------------|----------------------------------|---------------|--------------------------|-----------|\n",
      "| PCSK9 | PCSK9/LDLR binding assay | THP-1-derived macrophages | PCSK9 inhibitors | LDLR binding, autophagic flux | [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/) |\n",
      "| PCSK9 | CRISPR-Cas9 mediated PCSK9 knockout | ApoE-/- mice | CRISPR-Cas9 | Atherosclerotic plaque area, cholesterol levels | [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |\n",
      "| PCSK9 | PCSK9 immunization | Mouse model (e.g., C57BL/6) | Nanoliposomal PCSK9 vaccine | Atherosclerotic lesion size, LDL-C levels | [3](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |\n",
      "| PCSK9 | Gain-of-function mutant PCSK9 adeno-associated virus injection | Mice models | AAV-PCSK9 | Plaque size and composition, LDL-C levels | [4](https://pubmed.ncbi.nlm.nih.gov/27318830/) |\n",
      "| PCSK9 | Systemic injection of adenoviral PCSK9 | PCSK9-deficient mice | AdV-PCSK9 | Atherosclerosis development, inflammatory markers | [5](https://www.nature.com/articles/s41467-024-46336-2) |\n",
      "\n",
      "### ------------Target Engagement Analysis---------\n",
      "\n",
      "| Gene Name | Measurement Method | Target Engagement | Accessibility of Samples | Reference |\n",
      "|------------|--------------------|-------------------|------------------------|-----------|\n",
      "| PCSK9 | Competitive ELISA binding assay | Directly measure PCSK9 levels | Plasma (easily accessible) | [6](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |\n",
      "| PCSK9 | CRISPR-Cas9 mediated knockout efficiency check | Directly measure PCSK9 gene editing | Liver tissue | [7](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/) |\n",
      "| PCSK9 | Immunohistochemistry | Measure PCSK9 protein levels | Atherosclerotic Plaque tissue | [8](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |\n",
      "\n",
      "\n",
      "### ------------Disease Biomarker Analysis---------\n",
      "\n",
      "| Disease Name | Measurement | Measurement Method | Reference |\n",
      "|--------------|-------------|--------------------|-----------|\n",
      "| Atherosclerosis | LDL-C levels | Blood test (ELISA) | [9](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |\n",
      "| Atherosclerosis | Atherosclerotic plaque area | Histological staining | [10](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |\n",
      "\n",
      "\n",
      "### Rationale:\n",
      "- **In vitro Assays:** PCSK9/LDLR binding assays and use of THP-1-derived macrophages will help determine the effect of PCSK9 inhibition at the cellular level. Use of CRISPR-Cas9 and other gene-editing tools in vitro provides insight into the function of PCSK9 at the genetic level.\n",
      "- **In vivo Assays:** Animals such as ApoE-/- or PCSK9-deficient mice present the relevant disease context while allowing the study of PCSK9's role in atherosclerosis development. Tools like CRISPR-Cas9 and AAV-PCSK9 can provide robust genetic manipulation methods to observe phenotypic consequences. Nanoliposomal PCSK9 vaccines offer promising therapeutic avenues.\n",
      "- **Biomarkers/Phenotypes:** LDL-C levels and atherosclerotic plaque area are direct indicators of the disease state and efficacy of PCSK9 modulation.\n",
      "- **Target Engagement:** Methods like ELISA and immunohistochemistry validate the engagement and efficacy of gene-targeting approaches in accessible samples (plasma) and less accessible tissue (liver, plaque).\n",
      "\n",
      "### Conclusion:\n",
      "The compiled assays and measurement methods offer extensive avenues to validate the causal relationship between PCSK9 and atherosclerosis by leveraging molecular, genetic, and pharmacological tools. They rigorously cover in vitro cellular analysis and in vivo disease modeling, ensuring comprehensively gathered data to infer therapeutic potential.\n",
      "\n",
      "### References:\n",
      "1. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/\n",
      "   Quoted sentence: The in vitro experiments further showed that the PCSK9 inhibitor enhanced autophagic flux in ox-LDL-treated THP-1-derived macrophages.\n",
      "\n",
      "2. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/\n",
      "   Quoted sentence: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.\n",
      "\n",
      "3. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8\n",
      "   Quoted sentence: d In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies ... To assay the impact of L-IFPTA+ vaccine on atherosclerotic lesion.\n",
      "\n",
      "4. URL: https://pubmed.ncbi.nlm.nih.gov/27318830/\n",
      "   Quoted sentence: Jun 9, 2016 ... PCSK9 into mice promotes atherosclerosis.\n",
      "\n",
      "5. URL: https://www.nature.com/articles/s41467-024-46336-2\n",
      "   Quoted sentence: In vivo, systemic injection of AdV-PCSK9 significantly induced atherosclerosis.\n",
      "\n",
      "6. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/\n",
      "   Quoted sentence: Competitive ELISA binding assay showed that PCSK9-His can be effectively blocked.\n",
      "\n",
      "7. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/\n",
      "   Quoted sentence: The in vitro experiments further showed that the PCSK9 inhibitor enhanced autophagic flux in ox-LDL-treated THP-1-derived macrophages.\n",
      "\n",
      "8. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8\n",
      "   Quoted sentence: d In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies ...\n",
      "\n",
      "9. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/\n",
      "   Quoted sentence: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.\n",
      "\n",
      "10. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8\n",
      "    Quoted sentence: To assay the impact of L-IFPTA+ vaccine on atherosclerotic lesion ...\n",
      "\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "| Assayability - biomarkers & target engagement | Strong Positive (+1) | Weak Positive (+0.5) | Neutral (0) | Weak Negative (-0.5) | Strong Negative (-1) |\n",
      "| --- | --- | --- | --- | --- | --- |\n",
      "| --- | Treatment Efficacy and target engagement can be measured in plasma/non invasively | Either treatment efficacy or target engagement can be measured non-invasively. The other one needs to be measured in tissue. | Treatment Efficacy and target engagement can be measured in tissue. | Either treatment efficacy or target engagement need to be measured in a way that is more difficult than tissue inspection, e.g., biopsy.  | Treatment Efficacy and target engagement measurement need to be measured in a way that is more difficult than tissue inspection, e.g., biopsy. |\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **assayability of pcsk9**.\n",
      "\n",
      "Please use the table above to **rate the level of \n",
      "| Biomarker | Rating | Rationale of Rating |\n",
      "|-----------|--------|---------------------|\n",
      "|  | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong Positive (+1), Weak Positive (+0.5), Neutral (0), Weak Negative (-0.5), Negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      " based on a report user provided.** Each column represents a different level of \n",
      "| Biomarker | Rating | Rationale of Rating |\n",
      "|-----------|--------|---------------------|\n",
      "|  | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong Positive (+1), Weak Positive (+0.5), Neutral (0), Weak Negative (-0.5), Negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      ", from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "- Think about how the target engagement measurement can be done? (in plasma/non-invasively way or tissue)\n",
      "- Think about how the biomarker measurement can be done? (in plasma/non-invasively way or tissue)\n",
      "- NOTE: cannot be done in plasma/non-invasively way doesn't mean the target should be rated as negative scores.\n",
      "- Please be aware that the target engagement measurement has to **directly** measure the target gene. If it is not directly targeted, then it is not considered.\n",
      "\n",
      "- Criteria Guidance-\n",
      "- Strong positive (+1) is assigned if both the target engagement and biomarker measurement can be done in plasma/non-invasively way.\n",
      "- Weak positive (+0.5) is assigned if either target engagement or biomarker measurement can be done in plasma/non-invasively way.\n",
      "- Neutral (0) is assigned if both the target engagement and biomarker measurement can be done in tissue but cannot be done non-invasively.\n",
      "- Weak negative (-0.5) is assigned if either target engagement or biomarker measurement cannot be done easier than tissue inspection, e.g., biopsy. \n",
      "- Strong negative (-1) is assigned if both the target engagement and biomarker measurement  cannot be done easier than tissue inspection, e.g., biopsy.\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "report_pcsk9_all.md\n",
      "--------report chunk----------\n",
      "Druggability Report:\n",
      "\n",
      "### druggability\n",
      "### Collected Information on PCSK9\n",
      "\n",
      "| Gene name | Subcellular distribution | Tissue specific expression | Protein structure available? | Membrane protein | Ligand binder | Small molecule binder | Pocket | Small Molecule Tool Compound | Reference |\n",
      "|-----------|--------------------------|----------------------------|------------------------------|------------------|---------------|-----------------------|--------|------------------------------|-----------|\n",
      "| PCSK9     | Secreted protein           | Highly expressed in liver, detected in multiple tissues | Yes, crystal structure available (2.3 A)  |  No             | Yes           | Yes                   | Yes    | Compound 16, E28362, AZD0780 | [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]  |\n",
      "\n",
      "#### Detailed Analysis:\n",
      "\n",
      "1. **Gene Name**: PCSK9\n",
      "\n",
      "2. **Subcellular Distribution**:\n",
      "   - PCSK9 is primarily a secreted protein that acts extracellularly to regulate LDL receptor levels.\n",
      "\n",
      "3. **Tissue and Cell Type Specific Expression**:\n",
      "   - PCSK9 is highly expressed in the liver, but it is also detected in other tissues such as the intestine, kidneys, and central nervous system. This wide tissue distribution facilitates its systemic effects on cholesterol homeostasis.\n",
      "\n",
      "4. **Protein Structure**:\n",
      "   - The crystal structure of PCSK9 is available at 2.3 Å resolution. Detailed structural information allows precise targeting via small-molecule inhibitors or biologics.\n",
      "\n",
      "5. **Membrane Protein**:\n",
      "   - PCSK9 is not a membrane-bound protein itself but interacts with membrane receptors such as the LDL receptor, which is crucial for its function.\n",
      "\n",
      "6. **Ligand Binder**:\n",
      "   - PCSK9 binds to ligands, including its primary interaction partner, the LDL receptor, making it a feasible target for ligand-based inhibition strategies.\n",
      "\n",
      "7. **Small Molecule Binder**:\n",
      "   - Evidence shows that PCSK9 can bind small molecules in its receptor-binding domains. Small molecule inhibitors of PCSK9 have been explored, with some advancing to clinical studies.\n",
      "\n",
      "8. **Pocket**:\n",
      "   - Structural studies have identified binding pockets on PCSK9, including the LDL receptor interaction interface, supporting the development of compounds targeting these pockets.\n",
      "\n",
      "9. **Small Molecule Tool Compounds**:\n",
      "   - Several small molecule tool compounds, such as Compound 16, E28362, and AZD0780, have been identified. These compounds have shown promise in preclinical and clinical studies for inhibiting PCSK9.\n",
      "\n",
      "### Rationale for Suitable Modalities\n",
      "\n",
      "1. **Biologics (Monoclonal Antibodies)**:\n",
      "   - Targeting PCSK9 with monoclonal antibodies has been highly effective. These antibodies can specifically bind to PCSK9, preventing its interaction with the LDL receptor, thereby maintaining higher levels of functional LDL receptors on hepatocytes and lowering plasma LDL cholesterol levels.\n",
      "   - **Example**: Evolocumab, Alirocumab.\n",
      "\n",
      "2. **Small Molecule Inhibitors**:\n",
      "   - Small molecule inhibitors can bind to specific sites on PCSK9, blocking its interaction with the LDL receptor or promoting its degradation. The availability of its crystal structure facilitates the design of such molecules.\n",
      "   - **Examples**: Compounds such as Compound 16, E28362, and AZD0780 are in advanced stages of development.\n",
      "\n",
      "3. **Gene Therapy**:\n",
      "   - Gene editing technologies like CRISPR can be used to knock out or modify the PCSK9 gene to reduce its expression, providing a potentially long-term solution for patients with hypercholesterolemia.\n",
      "\n",
      "4. **RNA-based Therapies**:\n",
      "   - Antisense oligonucleotides or small interfering RNA (siRNA) targeting PCSK9 mRNA can reduce the production of PCSK9 in the liver, thereby decreasing its activity.\n",
      "   - **Example**: Inclisiran.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "Given its significant role in cholesterol metabolism and its well-characterized interaction with the LDL receptor, PCSK9 is druggable via multiple modalities:\n",
      "\n",
      "- **Biologics (Monoclonal antibodies)** and **Small Molecule Inhibitors** are the most promising and feasible approaches due to their ability to effectively inhibit the PCSK9-LDL receptor interaction, as evidenced by numerous clinical successes and available tool compounds.\n",
      "- **RNA-based therapies** and **Gene Therapy** offer innovative approaches for long-term regulation of PCSK9 levels and activity but require further development and testing.\n",
      "\n",
      "### References\n",
      "\n",
      "1. URL: https://pubmed.ncbi.nlm.nih.gov/26323289/\n",
      "   Quoted sentence: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.\n",
      "\n",
      "2. URL: https://www.proteinatlas.org/ENSG00000169174-PCSK9/tissue\n",
      "   Quoted sentence: PCSK9 is highly expressed in liver, detected in multiple tissues.\n",
      "\n",
      "3. URL: https://academic.oup.com/edrv/article/43/3/558/6385885\n",
      "   Quoted sentence: Here we report the crystal structure of human PCSK9 at 2.3 A resolution.\n",
      "\n",
      "4. URL: https://www.ncbi.nlm.nih.gov/gene/100102\n",
      "   Quoted sentence: PCSK9 belongs to the proteinase K family of subtilases, and its catalytic domain exhibits 25% of protein sequence identity to that of its closest family member.\n",
      "\n",
      "5. URL: https://pubs.acs.org/doi/10.1021/jacs.7b09360\n",
      "   Quoted sentence: This paper describes how side-chain orientations in preferred conformations of carefully designed chemotypes were compared with LDLR side chains at the PCSK9 interaction site.\n",
      "\n",
      "6. URL: https://www.nature.com/articles/s41401-024-01305-9\n",
      "   Quoted sentence: E28362 can block the interaction between PCSK9 and LDLR, induce the degradation of PCSK9, increase LDLR protein levels, and alleviate hyperlipidemia.\n",
      "\n",
      "7. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: Positive results from a Phase I trial of AZD0780, an oral small molecule PCSK9 inhibitor administered on top of statin treatment, were presented.\n",
      "\n",
      "8. URL: https://www.sciencedirect.com/science/article/pii/S2451945619303228\n",
      "   Quoted sentence: Analysis of the binding interface between the two proteins sheds light on the difficulty in identifying small-molecule ligands for PCSK9.\n",
      "\n",
      "9. URL: https://www.mdpi.com/2227-9059/12/2/286\n",
      "   Quoted sentence: PCSK9 inhibitors, also referred to as PCSK9i, are highly potent medications for reducing LDL-C levels, significantly enhancing our capacity to manage hypercholesterolemia.\n",
      "\n",
      "10. URL: https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202400208\n",
      "   Quoted sentence: Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9.\n",
      "\n",
      "\n",
      "------------------\n",
      "Competitive Edge Report:\n",
      "\n",
      "### competitive_edge\n",
      "Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.\n",
      "\n",
      "### Small Molecules\n",
      "\n",
      "| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |\n",
      "| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |\n",
      "| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |\n",
      "\n",
      "### Antibodies\n",
      "\n",
      "| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "\n",
      "### siRNA\n",
      "\n",
      "| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |\n",
      "| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |\n",
      "\n",
      "### Rationale\n",
      "The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.\n",
      "\n",
      "### Conclusion\n",
      "Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:\n",
      "- **Small molecules:** Phase 2b (MK-0616)\n",
      "- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)\n",
      "- **siRNA:** Phase 3 (Inclisiran)\n",
      "\n",
      "### References\n",
      "1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: \"AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.\"\n",
      "\n",
      "2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/\n",
      "   Quoted sentence: \"MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study.\"\n",
      "\n",
      "3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx\n",
      "   Quoted sentence: \"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research.\"\n",
      "\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080\n",
      "   Quoted sentence: \"Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events.\"\n",
      "\n",
      "5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/\n",
      "   Quoted sentence: \"The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials.\"\n",
      "\n",
      "6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/\n",
      "   Quoted sentence: \"Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials.\"\n",
      "\n",
      "7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full\n",
      "   Quoted sentence: \"Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes.\"\n",
      "\n",
      "8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions\n",
      "   Quoted sentence: \"Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|     | strong - positive (+1)                                                                 | Weak - positive (+0.5)                                                              | neutral (0)                  | Weak negative (-0.5)                                             | Strong negative (-1)         |\n",
      "|-----|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------|------------------------------|\n",
      "| | There are antibody drugs in clinical trials or on the market                           | There are experimental antibodies that have been developed and shown to modulate target activity | Cell surface or secreted proteins | Cross blood brain barrier needed for modulating the target       | Intracellular protein        |\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **suitability of antibodies targeting the pcsk9**.\n",
      "\n",
      "Please use the table above to **rate the level of suitability of antibodies for pcsk9 based on a report user provided.** Each column represents a different level of suitability of antibodies for pcsk9, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "- If there are antibody drugs in clinical trial or being approved , it **means the target is strong positive (+1)**. NOTE: The drug has to **directly target** the target gene.\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Data Availability | Rating | Rationale of Rating |\n",
      "|--------------------|--------|---------------------|\n",
      "| Are there any existing antibodies drugs on pcsk9? <br> Are experimental antibodies available that modulates the target pcsk9? | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "--------report chunk----------\n",
      "In Vitro Report:\n",
      "\n",
      "### in_vitro_or_vivo_data\n",
      "Based on the collected information, here is a summary of the experimental evidence supporting the involvement of the PCSK9 gene in atherosclerosis:\n",
      "\n",
      "| Gene name | Experimental evidence | Clinical Trial/Cell/Animal Model Used | Key Results | Reference |\n",
      "|-----------|-----------------------|---------------------------------------|-------------|-----------|\n",
      "| **PCSK9** | Study 1: Recent Update on PCSK9 and Platelet Activation Experimental | In vitro and in vivo models using isolated platelets and animal models | Beyond its lipid-lowering effect, PCSK9 also mediates platelet activation, which contributes to the progression of atherosclerosis. | [1](https://www.mdpi.com/2308-3425/9/8/258) |\n",
      "|           | Study 2: Pharmacological modulation of LDL receptor by small interfering RNA and antibodies anti-PCSK9 | In vitro study on hepatocytes | Pharmacological modulation of LDL receptor by PCSK9 inhibitors shows enhanced LDL uptake by hepatocytes, which can reduce atherosclerosis risk. | [2](https://www.atherosclerosis-journal.com/article/S0021-9150(24)00392-7/abstract) |\n",
      "|           | Study 3: The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in human atherosclerotic plaques | In vitro and in vivo studies on vascular smooth muscle cells and human plaques | PCSK9 secreted by vascular smooth muscle cells and within plaques reduces LDL receptor levels, contributing to atherosclerotic processes. | [3](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1431398/full) |\n",
      "|           | Study 4: Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Mendelian Randomization Analyses | In vivo studies in mice models and human clinical studies | PCSK9 inhibitors have pleiotropic effects that reduce inflammation and oxidative stress in addition to lowering LDL-C levels. | [4](https://www.unmc.edu/intmed/_documents/cardiology/cbbl/2018-4.pdf) |\n",
      "|           | Study 5: Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Triggers Apoptosis in Human Abdominal Aortic Aneurysm Smooth Muscle Cells | In vivo and in vitro studies on human and mouse models | PCSK9 promotes apoptosis in vascular smooth muscle cells, contributing to the instability of atherosclerotic plaques. | [5](https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316902) |\n",
      "|           | Study 6: Gene Therapy Targeting PCSK9 | In vitro and in vivo gene editing studies | Gene editing targeting PCSK9 splice sites shows potential for reducing cholesterol levels and atherosclerosis. | [6](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/) |\n",
      "|           | Study 7: PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vivo | In vivo studies in murine models | PCSK9's inflammatory effects are largely independent of chemokine receptors, indicating alternate pathways in atherosclerosis. | [7](https://pubmed.ncbi.nlm.nih.gov/34884827/) |\n",
      "\n",
      "### Rationale:\n",
      "The body of evidence from various controlled in vitro and in vivo experiments demonstrates that PCSK9 plays a significant role in the development and progression of atherosclerosis. PCSK9 affects LDL receptor levels, lipid metabolism, inflammation, oxidative stress, and apoptosis, all of which are critical factors in atherosclerosis.\n",
      "\n",
      "### Conclusion:\n",
      "Expression and action of PCSK9 contribute significantly to atherosclerosis through multiple pathways involving lipid metabolism, inflammatory responses, and stability of atherosclerotic plaques. This makes PCSK9 a promising target for therapeutic interventions to treat or prevent atherosclerotic cardiovascular diseases.\n",
      "\n",
      "### References:\n",
      "1. URL: https://www.mdpi.com/2308-3425/9/8/258\n",
      "   Quoted sentence: \"Beyond its lipid-lowering effect, accumulative evidence has shown the implication of PCSK9 in platelet activation and its role in cardiovascular diseases including atherosclerosis.\"\n",
      "\n",
      "2. URL: https://www.atherosclerosis-journal.com/article/S0021-9150(24)00392-7/abstract\n",
      "   Quoted sentence: \"Pharmacological modulation of LDL receptor by PCSK9 inhibitors preserves the levels of surface LDL-R and enhances LDL uptake by hepatocytes.\"\n",
      "\n",
      "3. URL: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1431398/full\n",
      "   Quoted sentence: \"PCSK9 secreted by vascular smooth muscle cells and within plaques reduces LDL receptor levels, contributing to atherosclerotic processes.\"\n",
      "\n",
      "4. URL: https://www.unmc.edu/intmed/_documents/cardiology/cbbl/2018-4.pdf\n",
      "   Quoted sentence: \"In vivo studies demonstrate that PCSK9 inhibitors have pleiotropic effects that reduce inflammation and oxidative stress in addition to lowering LDL-C levels.\"\n",
      "\n",
      "5. URL: https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316902\n",
      "   Quoted sentence: \"PCSK9 promotes apoptosis in vascular smooth muscle cells, contributing to the instability of atherosclerotic plaques.\"\n",
      "\n",
      "6. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/\n",
      "   Quoted sentence: \"Gene editing targeting PCSK9 splice sites shows potential for reducing cholesterol levels and atherosclerosis.\"\n",
      "\n",
      "7. URL: https://pubmed.ncbi.nlm.nih.gov/34884827/\n",
      "   Quoted sentence: \"PCSK9's inflammatory effects are largely independent of chemokine receptors, indicating alternate pathways in atherosclerosis.\"\n",
      "\n",
      "\n",
      "------------------\n",
      "Safety Evaluation Report:\n",
      "\n",
      "### safety\n",
      "### Summary of Safety Profile of PCSK9 Inhibitors and Gene Manipulation\n",
      "\n",
      "#### Safety Profile in Approved Drugs Targeting PCSK9\n",
      "\n",
      "1. **Safety of PCSK9 Inhibitors**:\n",
      "   - **General Safety Profile**: PCSK9 inhibitors, such as alirocumab and evolocumab, generally exhibit a good safety profile. Common adverse events include musculoskeletal and connective tissue disorders, local injection site reactions, and mild-to-moderate adverse events, but serious safety concerns are rare within the clinical data.\n",
      "     - References:\n",
      "       - Real-world safety of PCSK9 inhibitors: \"Compared with all other drugs, PCSK9 inhibitors were associated with an increased reporting risk of musculoskeletal and connective tissue disorders...\" ([Source](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.894685/full))\n",
      "       - Safety of PCSK9 inhibitors: \"...PCSK9 inhibitors have been shown to be a safe, tolerable and effective treatment for hyperlipidaemia in patients with markedly elevated CPK values. The ODYSSEY...\" ([Source](https://www.sciencedirect.com/science/article/pii/S0753332222013464))\n",
      "       - Safety and Tolerability of PCSK9 Inhibitors: \"...safety and efficacy of the drugs.\" ([Source](https://pmc.ncbi.nlm.nih.gov/articles/PMC7737942/))\n",
      "\n",
      "2. **Specific Drug Safety Reports**:\n",
      "   - **Alirocumab**: The safety profile of alirocumab was very similar to that of a matching placebo, except for a slight increase in local injection site reactions.\n",
      "     - Reference: \"The safety profile of alirocumab was indistinguishable from matching placebo except for a 1.7% absolute increase in local injection site reactions.\" ([Source](https://academic.oup.com/ehjcvp/article/10/4/342/7657797))\n",
      "\n",
      "   - **Evolocumab**: Evolocumab exhibits good safety and tolerability, with predominantly mild to moderate adverse events.\n",
      "     - Reference: \"...Evolocumab reportedly exhibit good safety and tolerability, along with predominantly mild-to-moderate adverse events (AEs)...\" ([Source](https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15460))\n",
      "\n",
      "3. **Drug Safety in Clinical and Gene Editing Trials**:\n",
      "   - Research and clinical trials involving gene editing and small interfering RNA targeting PCSK9 have shown varying results. Specifically, concerns have emerged regarding the safety of using advanced gene-editing techniques like CRISPR.\n",
      "     - Reference: \"Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns...\" ([Source](https://www.biospace.com/article/releases/verve-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-updates/))\n",
      "\n",
      "#### Adversary Phenotype of Target Gene Knockout Mice\n",
      "\n",
      "| Gene name | Safety issues have been reported in clinic | Human disease or traits linked to target gene mutation | Adversary Phenotype of target gene knockout mice (In addition to desired therapeutic effects) |\n",
      "|-----------|-------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------|\n",
      "| **PCSK9** | 1. Safety confirmed in several studies, with mild to moderate adverse effects reported.                                                                                                                                                      | 1. Family history of hypercholesterolemia implicated with PCSK9 mutations<br>2. Adverse cardiovascular effects in some gene-edited treatments.<br>3. PCSK9 mutations impact cholesterol metabolism and increase CVD risks. | 1. **Microvascular dysfunction**: PCSK9 knockout mice displayed increased incidence of microvascular dysfunction.<br>2. **Atherosclerosis-related genes**: Upregulation of genes linked to cardiovascular conditions in knockout models. |\n",
      "\n",
      "### Rationale\n",
      "Based on various experimental and clinical data, it is apparent that PCSK9 inhibitors offer a generally safe profile with predominant mild to moderate adverse effects. However, gene editing programs concerning PCSK9 have shown varying results and raised safety concerns. Knockout mice studies portrayed increased risks related to cardiovascular diseases and microvascular dysfunctions, highlighting the need for meticulous safety evaluations in therapeutic applications targeting PCSK9.\n",
      " \n",
      "### Conclusion\n",
      "While PCSK9 inhibitors are considered relatively safe in clinical use, the risk profiles for gene-editing therapies targeting PCSK9 demand further thorough investigations. Careful consideration must be given to the potential adverse effects before introducing novel therapeutic strategies into regular clinical practice.\n",
      "\n",
      "### References:\n",
      "[1] URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.894685/full\n",
      "   Quoted sentence: \"Compared with all other drugs, PCSK9 inhibitors were associated with an increased reporting risk of musculoskeletal and connective tissue disorders...\"\n",
      "\n",
      "[2] URL: https://www.sciencedirect.com/science/article/pii/S0753332222013464\n",
      "   Quoted sentence: \"...PCSK9 inhibitors have been shown to be a safe, tolerable and effective treatment for hyperlipidaemia in patients with markedly elevated CPK values. The ODYSSEY...\"\n",
      "\n",
      "[3] URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7737942/\n",
      "   Quoted sentence: \"...safety and efficacy of the drugs.\"\n",
      "\n",
      "[4] URL: https://academic.oup.com/ehjcvp/article/10/4/342/7657797\n",
      "   Quoted sentence: \"The safety profile of alirocumab was indistinguishable from matching placebo except for a 1.7% absolute increase in local injection site reactions.\"\n",
      "\n",
      "[5] URL: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15460\n",
      "   Quoted sentence: \"Alirocumab and evolocumab reportedly exhibit good safety and tolerability, along with predominantly mild-to-moderate adverse events (AEs)...\"\n",
      "\n",
      "[6] URL: https://www.biospace.com/article/releases/verve-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-updates/\n",
      "   Quoted sentence: \"Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns ...\"\n",
      "\n",
      "[7] URL: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1338458/full\n",
      "   Quoted sentence: \"All these genes were upregulated in aortas of PCSK9DY-positive mice, too. As Sirtuin 1 (Sirt1) has been shown to be important to cardiovascular disease,...\"\n",
      "\n",
      "[8] URL: https://academic.oup.com/ehjcvp/article/10/4/342/7657797\n",
      "   Quoted sentence: \"safety; pcsk9 gene; adverse event; alirocumab. Issue Section: Review. Introduction. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/...\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "| Rating                   | Strong Positive (+1)                                                                  | Weak Positive (+0.5)                                                        | Neutral (0)                                                                  | Weak Negative (-0.5)                                                      | Strong Negative (-1)                             |\n",
      "|--------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------|\n",
      "| Description              | -**Human** variants are healthy in clinical programme for pcsk9 in atherosclerosis. OR - Have drugs approved and are generally considered safe, i.e., shows a favorable safety profile in humans and no severe side effects.            | No side effects or safety issue has been identified in **mice or other animal models**.    | There is no studies have been conducted, e.g., animal models or clinical trials.                                            | - **Severe side effect or safety issues** have been identified in **mice or other animal models.** | - Clinical programs tested but failed due to safety issues.  OR  - **Severe side effects** (side effects means adversary phenotype in addition to desired therapeutic effects) have been detected in humans|\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **safety of targeting pcsk9 for atherosclerosis**.\n",
      "\n",
      "Please use the table above to **rate the level of safety of pcsk9 for atherosclerosis based on a report user provided.** Each column represents a different level of safety of pcsk9 for atherosclerosis, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Safety-related Information | Rating | Rationale of Rating |\n",
      "|-----------------------------|--------|---------------------|\n",
      "| What is the desired therapeutic effect of pcsk9 for atherosclerosis? Are there any approved drugs targeting pcsk9 for atherosclerosis? If yes, are they generally considered as safe? Are there any animal studies of pcsk9? Are there any side effects in these animal studies? | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "--------report chunk----------\n",
      "In Vitro Report:\n",
      "\n",
      "### in_vitro_or_vivo_data\n",
      "Based on the collected information, here is a summary of the experimental evidence supporting the involvement of the PCSK9 gene in atherosclerosis:\n",
      "\n",
      "| Gene name | Experimental evidence | Clinical Trial/Cell/Animal Model Used | Key Results | Reference |\n",
      "|-----------|-----------------------|---------------------------------------|-------------|-----------|\n",
      "| **PCSK9** | Study 1: Recent Update on PCSK9 and Platelet Activation Experimental | In vitro and in vivo models using isolated platelets and animal models | Beyond its lipid-lowering effect, PCSK9 also mediates platelet activation, which contributes to the progression of atherosclerosis. | [1](https://www.mdpi.com/2308-3425/9/8/258) |\n",
      "|           | Study 2: Pharmacological modulation of LDL receptor by small interfering RNA and antibodies anti-PCSK9 | In vitro study on hepatocytes | Pharmacological modulation of LDL receptor by PCSK9 inhibitors shows enhanced LDL uptake by hepatocytes, which can reduce atherosclerosis risk. | [2](https://www.atherosclerosis-journal.com/article/S0021-9150(24)00392-7/abstract) |\n",
      "|           | Study 3: The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in human atherosclerotic plaques | In vitro and in vivo studies on vascular smooth muscle cells and human plaques | PCSK9 secreted by vascular smooth muscle cells and within plaques reduces LDL receptor levels, contributing to atherosclerotic processes. | [3](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1431398/full) |\n",
      "|           | Study 4: Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Mendelian Randomization Analyses | In vivo studies in mice models and human clinical studies | PCSK9 inhibitors have pleiotropic effects that reduce inflammation and oxidative stress in addition to lowering LDL-C levels. | [4](https://www.unmc.edu/intmed/_documents/cardiology/cbbl/2018-4.pdf) |\n",
      "|           | Study 5: Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Triggers Apoptosis in Human Abdominal Aortic Aneurysm Smooth Muscle Cells | In vivo and in vitro studies on human and mouse models | PCSK9 promotes apoptosis in vascular smooth muscle cells, contributing to the instability of atherosclerotic plaques. | [5](https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316902) |\n",
      "|           | Study 6: Gene Therapy Targeting PCSK9 | In vitro and in vivo gene editing studies | Gene editing targeting PCSK9 splice sites shows potential for reducing cholesterol levels and atherosclerosis. | [6](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/) |\n",
      "|           | Study 7: PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vivo | In vivo studies in murine models | PCSK9's inflammatory effects are largely independent of chemokine receptors, indicating alternate pathways in atherosclerosis. | [7](https://pubmed.ncbi.nlm.nih.gov/34884827/) |\n",
      "\n",
      "### Rationale:\n",
      "The body of evidence from various controlled in vitro and in vivo experiments demonstrates that PCSK9 plays a significant role in the development and progression of atherosclerosis. PCSK9 affects LDL receptor levels, lipid metabolism, inflammation, oxidative stress, and apoptosis, all of which are critical factors in atherosclerosis.\n",
      "\n",
      "### Conclusion:\n",
      "Expression and action of PCSK9 contribute significantly to atherosclerosis through multiple pathways involving lipid metabolism, inflammatory responses, and stability of atherosclerotic plaques. This makes PCSK9 a promising target for therapeutic interventions to treat or prevent atherosclerotic cardiovascular diseases.\n",
      "\n",
      "### References:\n",
      "1. URL: https://www.mdpi.com/2308-3425/9/8/258\n",
      "   Quoted sentence: \"Beyond its lipid-lowering effect, accumulative evidence has shown the implication of PCSK9 in platelet activation and its role in cardiovascular diseases including atherosclerosis.\"\n",
      "\n",
      "2. URL: https://www.atherosclerosis-journal.com/article/S0021-9150(24)00392-7/abstract\n",
      "   Quoted sentence: \"Pharmacological modulation of LDL receptor by PCSK9 inhibitors preserves the levels of surface LDL-R and enhances LDL uptake by hepatocytes.\"\n",
      "\n",
      "3. URL: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1431398/full\n",
      "   Quoted sentence: \"PCSK9 secreted by vascular smooth muscle cells and within plaques reduces LDL receptor levels, contributing to atherosclerotic processes.\"\n",
      "\n",
      "4. URL: https://www.unmc.edu/intmed/_documents/cardiology/cbbl/2018-4.pdf\n",
      "   Quoted sentence: \"In vivo studies demonstrate that PCSK9 inhibitors have pleiotropic effects that reduce inflammation and oxidative stress in addition to lowering LDL-C levels.\"\n",
      "\n",
      "5. URL: https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316902\n",
      "   Quoted sentence: \"PCSK9 promotes apoptosis in vascular smooth muscle cells, contributing to the instability of atherosclerotic plaques.\"\n",
      "\n",
      "6. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/\n",
      "   Quoted sentence: \"Gene editing targeting PCSK9 splice sites shows potential for reducing cholesterol levels and atherosclerosis.\"\n",
      "\n",
      "7. URL: https://pubmed.ncbi.nlm.nih.gov/34884827/\n",
      "   Quoted sentence: \"PCSK9's inflammatory effects are largely independent of chemokine receptors, indicating alternate pathways in atherosclerosis.\"\n",
      "\n",
      "\n",
      "------------------\n",
      "Competitive Edge Report:\n",
      "\n",
      "### competitive_edge\n",
      "Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.\n",
      "\n",
      "### Small Molecules\n",
      "\n",
      "| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |\n",
      "| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |\n",
      "| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |\n",
      "\n",
      "### Antibodies\n",
      "\n",
      "| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |\n",
      "\n",
      "### siRNA\n",
      "\n",
      "| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |\n",
      "|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|\n",
      "| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |\n",
      "| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |\n",
      "\n",
      "### Rationale\n",
      "The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.\n",
      "\n",
      "### Conclusion\n",
      "Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:\n",
      "- **Small molecules:** Phase 2b (MK-0616)\n",
      "- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)\n",
      "- **siRNA:** Phase 3 (Inclisiran)\n",
      "\n",
      "### References\n",
      "1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: \"AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia.\"\n",
      "\n",
      "2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/\n",
      "   Quoted sentence: \"MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study.\"\n",
      "\n",
      "3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx\n",
      "   Quoted sentence: \"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research.\"\n",
      "\n",
      "4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080\n",
      "   Quoted sentence: \"Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events.\"\n",
      "\n",
      "5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/\n",
      "   Quoted sentence: \"The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials.\"\n",
      "\n",
      "6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/\n",
      "   Quoted sentence: \"Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials.\"\n",
      "\n",
      "7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full\n",
      "   Quoted sentence: \"Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes.\"\n",
      "\n",
      "8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions\n",
      "   Quoted sentence: \"Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk.\"\n",
      "\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|                           | Strong - positive (+1)                               | Weak - positive (+0.5)                                                   | Neutral (0)                                    | Weak negative (-0.5)                                                       | Strong negative (-1)                             |\n",
      "|---------------------------|-----------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------|\n",
      "|  | In human perturbation (i.e., clinical trials) of the target gene modulates disease progression | **Both Cell & In animal perturbation** of the target gene modulates disease progression | **Only Cell** perturbation of the target gene modulates disease progression | **Conflict results** upon target gene perturbation in disease associated experimental model | Clinical programme tested but failed due to lack of efficacy |\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **strength of target pcsk9 and atherosclerosis disease progression evidence based on found in vitro/vivo experiments**.\n",
      "\n",
      "Please use the table above to **rate the level of evidence supporting pcsk9 role in atherosclerosis disease progression based on a report user provided.** Each column represents a different level of evidence supporting pcsk9 role in atherosclerosis disease progression, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "- Read competitive edge reports to identify if there is clinical trials evidence supporting the gene's role in the disease.\n",
      "- If there is clinical trial (i.e., in human perturbation) evidence directly supporting the gene's role in the disease, then it is a **strong positive (+1)**.\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Evidence supporting target gene and disease progression | Rating | Rationale of Rating |\n",
      "|---------------------------------------------------------|--------|---------------------|\n",
      "| Is pcsk9 for atherosclerosis being evaluated on in human, cell or animal perturbation? Any conflict results? | After evaluating the content, select a category from the following options: [Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]. **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "    \n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/yzhe0006/models/TargetSeek_Code/Target_Scoring_AgentScorer/tools.py:356: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  gene_info[\"Expression Level\"] = gene_info[\"nTPM\"].apply(categorize_expression)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--------report chunk----------\n",
      "Druggability Report:\n",
      "\n",
      "### druggability\n",
      "### Collected Information on PCSK9\n",
      "\n",
      "| Gene name | Subcellular distribution | Tissue specific expression | Protein structure available? | Membrane protein | Ligand binder | Small molecule binder | Pocket | Small Molecule Tool Compound | Reference |\n",
      "|-----------|--------------------------|----------------------------|------------------------------|------------------|---------------|-----------------------|--------|------------------------------|-----------|\n",
      "| PCSK9     | Secreted protein           | Highly expressed in liver, detected in multiple tissues | Yes, crystal structure available (2.3 A)  |  No             | Yes           | Yes                   | Yes    | Compound 16, E28362, AZD0780 | [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]  |\n",
      "\n",
      "#### Detailed Analysis:\n",
      "\n",
      "1. **Gene Name**: PCSK9\n",
      "\n",
      "2. **Subcellular Distribution**:\n",
      "   - PCSK9 is primarily a secreted protein that acts extracellularly to regulate LDL receptor levels.\n",
      "\n",
      "3. **Tissue and Cell Type Specific Expression**:\n",
      "   - PCSK9 is highly expressed in the liver, but it is also detected in other tissues such as the intestine, kidneys, and central nervous system. This wide tissue distribution facilitates its systemic effects on cholesterol homeostasis.\n",
      "\n",
      "4. **Protein Structure**:\n",
      "   - The crystal structure of PCSK9 is available at 2.3 Å resolution. Detailed structural information allows precise targeting via small-molecule inhibitors or biologics.\n",
      "\n",
      "5. **Membrane Protein**:\n",
      "   - PCSK9 is not a membrane-bound protein itself but interacts with membrane receptors such as the LDL receptor, which is crucial for its function.\n",
      "\n",
      "6. **Ligand Binder**:\n",
      "   - PCSK9 binds to ligands, including its primary interaction partner, the LDL receptor, making it a feasible target for ligand-based inhibition strategies.\n",
      "\n",
      "7. **Small Molecule Binder**:\n",
      "   - Evidence shows that PCSK9 can bind small molecules in its receptor-binding domains. Small molecule inhibitors of PCSK9 have been explored, with some advancing to clinical studies.\n",
      "\n",
      "8. **Pocket**:\n",
      "   - Structural studies have identified binding pockets on PCSK9, including the LDL receptor interaction interface, supporting the development of compounds targeting these pockets.\n",
      "\n",
      "9. **Small Molecule Tool Compounds**:\n",
      "   - Several small molecule tool compounds, such as Compound 16, E28362, and AZD0780, have been identified. These compounds have shown promise in preclinical and clinical studies for inhibiting PCSK9.\n",
      "\n",
      "### Rationale for Suitable Modalities\n",
      "\n",
      "1. **Biologics (Monoclonal Antibodies)**:\n",
      "   - Targeting PCSK9 with monoclonal antibodies has been highly effective. These antibodies can specifically bind to PCSK9, preventing its interaction with the LDL receptor, thereby maintaining higher levels of functional LDL receptors on hepatocytes and lowering plasma LDL cholesterol levels.\n",
      "   - **Example**: Evolocumab, Alirocumab.\n",
      "\n",
      "2. **Small Molecule Inhibitors**:\n",
      "   - Small molecule inhibitors can bind to specific sites on PCSK9, blocking its interaction with the LDL receptor or promoting its degradation. The availability of its crystal structure facilitates the design of such molecules.\n",
      "   - **Examples**: Compounds such as Compound 16, E28362, and AZD0780 are in advanced stages of development.\n",
      "\n",
      "3. **Gene Therapy**:\n",
      "   - Gene editing technologies like CRISPR can be used to knock out or modify the PCSK9 gene to reduce its expression, providing a potentially long-term solution for patients with hypercholesterolemia.\n",
      "\n",
      "4. **RNA-based Therapies**:\n",
      "   - Antisense oligonucleotides or small interfering RNA (siRNA) targeting PCSK9 mRNA can reduce the production of PCSK9 in the liver, thereby decreasing its activity.\n",
      "   - **Example**: Inclisiran.\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "Given its significant role in cholesterol metabolism and its well-characterized interaction with the LDL receptor, PCSK9 is druggable via multiple modalities:\n",
      "\n",
      "- **Biologics (Monoclonal antibodies)** and **Small Molecule Inhibitors** are the most promising and feasible approaches due to their ability to effectively inhibit the PCSK9-LDL receptor interaction, as evidenced by numerous clinical successes and available tool compounds.\n",
      "- **RNA-based therapies** and **Gene Therapy** offer innovative approaches for long-term regulation of PCSK9 levels and activity but require further development and testing.\n",
      "\n",
      "### References\n",
      "\n",
      "1. URL: https://pubmed.ncbi.nlm.nih.gov/26323289/\n",
      "   Quoted sentence: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.\n",
      "\n",
      "2. URL: https://www.proteinatlas.org/ENSG00000169174-PCSK9/tissue\n",
      "   Quoted sentence: PCSK9 is highly expressed in liver, detected in multiple tissues.\n",
      "\n",
      "3. URL: https://academic.oup.com/edrv/article/43/3/558/6385885\n",
      "   Quoted sentence: Here we report the crystal structure of human PCSK9 at 2.3 A resolution.\n",
      "\n",
      "4. URL: https://www.ncbi.nlm.nih.gov/gene/100102\n",
      "   Quoted sentence: PCSK9 belongs to the proteinase K family of subtilases, and its catalytic domain exhibits 25% of protein sequence identity to that of its closest family member.\n",
      "\n",
      "5. URL: https://pubs.acs.org/doi/10.1021/jacs.7b09360\n",
      "   Quoted sentence: This paper describes how side-chain orientations in preferred conformations of carefully designed chemotypes were compared with LDLR side chains at the PCSK9 interaction site.\n",
      "\n",
      "6. URL: https://www.nature.com/articles/s41401-024-01305-9\n",
      "   Quoted sentence: E28362 can block the interaction between PCSK9 and LDLR, induce the degradation of PCSK9, increase LDLR protein levels, and alleviate hyperlipidemia.\n",
      "\n",
      "7. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html\n",
      "   Quoted sentence: Positive results from a Phase I trial of AZD0780, an oral small molecule PCSK9 inhibitor administered on top of statin treatment, were presented.\n",
      "\n",
      "8. URL: https://www.sciencedirect.com/science/article/pii/S2451945619303228\n",
      "   Quoted sentence: Analysis of the binding interface between the two proteins sheds light on the difficulty in identifying small-molecule ligands for PCSK9.\n",
      "\n",
      "9. URL: https://www.mdpi.com/2227-9059/12/2/286\n",
      "   Quoted sentence: PCSK9 inhibitors, also referred to as PCSK9i, are highly potent medications for reducing LDL-C levels, significantly enhancing our capacity to manage hypercholesterolemia.\n",
      "\n",
      "10. URL: https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202400208\n",
      "   Quoted sentence: Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9.\n",
      "\n",
      "\n",
      "------------------\n",
      "Tissue Distribution Report:\n",
      "| Tissue Type | Expression Value | Expression Level |\n",
      "|-------------|------------------|------------------|\n",
      "| liver | 47.6 | Moderate |\n",
      "| cerebellum | 10.1 | Moderate |\n",
      "| lung | 7.6 | Low |\n",
      "| esophagus | 5.3 | Low |\n",
      "| pancreas | 5.2 | Low |\n",
      "| colon | 4.4 | Very Low |\n",
      "| small intestine | 3.3 | Very Low |\n",
      "| duodenum | 3.0 | Very Low |\n",
      "| rectum | 1.5 | Very Low |\n",
      "| vagina | 1.5 | Very Low |\n",
      "| stomach | 1.3 | Very Low |\n",
      "| skin | 1.3 | Very Low |\n",
      "| cervix | 1.0 | Very Low |\n",
      "| smooth muscle | 0.7 | Very Low |\n",
      "| appendix | 0.7 | Very Low |\n",
      "| testis | 0.4 | Very Low |\n",
      "| bone marrow | 0.4 | Very Low |\n",
      "| fallopian tube | 0.4 | Very Low |\n",
      "| salivary gland | 0.4 | Very Low |\n",
      "| spleen | 0.3 | Very Low |\n",
      "| tonsil | 0.3 | Very Low |\n",
      "| urinary bladder | 0.3 | Very Low |\n",
      "| adipose tissue | 0.3 | Very Low |\n",
      "| endometrium | 0.3 | Very Low |\n",
      "| epididymis | 0.3 | Very Low |\n",
      "| seminal vesicle | 0.2 | Very Low |\n",
      "| adrenal gland | 0.2 | Very Low |\n",
      "| basal ganglia | 0.2 | Very Low |\n",
      "| parathyroid gland | 0.2 | Very Low |\n",
      "| spinal cord | 0.2 | Very Low |\n",
      "| kidney | 0.1 | Very Low |\n",
      "| breast | 0.1 | Very Low |\n",
      "| cerebral cortex | 0.1 | Very Low |\n",
      "| gallbladder | 0.1 | Very Low |\n",
      "| midbrain | 0.1 | Very Low |\n",
      "| pituitary gland | 0.1 | Very Low |\n",
      "| hypothalamus | 0.1 | Very Low |\n",
      "| ovary | 0.1 | Very Low |\n",
      "| heart muscle | 0.0 | Very Low |\n",
      "| lymph node | 0.0 | Very Low |\n",
      "| retina | 0.0 | Very Low |\n",
      "| hippocampal formation | 0.0 | Very Low |\n",
      "| prostate | 0.0 | Very Low |\n",
      "| placenta | 0.0 | Very Low |\n",
      "| choroid plexus | 0.0 | Very Low |\n",
      "| thymus | 0.0 | Very Low |\n",
      "| thyroid gland | 0.0 | Very Low |\n",
      "| tongue | 0.0 | Very Low |\n",
      "| amygdala | 0.0 | Very Low |\n",
      "| skeletal muscle | 0.0 | Very Low |\n",
      "\n",
      "--------instruction----------\n",
      "\n",
      "\n",
      "|     |          | strong - positive (+1) | Weak - positive (+0.5) | neutral (0) | Weak negative (-0.5) | Strong negative (-1) |\n",
      "|-----|----------|-------------------------|------------------------|-------------|----------------------|-----------------------|\n",
      "|   | siRNA    | Target gene mainly expressed and function in hepatocytes. | The target gene is primarily expressed and functions in the CNS, muscle, adipose tissue, or blood cells. | No good sirna strategy so far and therapeutic direction is not clear. | Target exon skipping is needed as a therapeutics for the intended disease | Target activation needed as a therapeutics for the intended disease |\n",
      "\n",
      "    **************************\n",
      "You are a genetic researcher tasked with evaluating **suitability of siRNA targeting the pcsk9**.\n",
      "\n",
      "Please use the table above to **rate the level of suitability of siRNA for pcsk9 based on a report user provided.** Each column represents a different level of suitability of siRNA for pcsk9, from strong positive to strong negative. Carefully consider the evidence and select the most appropriate rating based on the descriptions provided in the table.\n",
      "\n",
      "\n",
      "\n",
      "Output Format:\n",
      "\n",
      "| Tissue Distribution | Rating | Rationale of Rating |\n",
      "|---------------------|--------|---------------------|\n",
      "| Which tissues and organs are the target pcsk9 mainly expressed? Which tissues and organs are the target pcsk9 mainly function? Are there good sirna strategy so far and is the therapeutic direction clear? | After evaluating the content, you **can only select a category from the following options**: <br> **[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "| After evaluating the content, you **can only select a category from the following options**: <br> **[Strong - positive (+1), Weak - positive (+0.5), Neutral (0), Weak - negative (-0.5), Strong - negative (-1)]** <br> **Only put the category and say nothing else** | Illustrate why you give this rating |\n",
      "\n",
      "\n",
      "Please organize your output according to the Output Format. Fill in each cell based on descriptions in each cell. If the Output Format is empty, you can ignore it.\n",
      "    \n",
      "--------scoring result----------\n",
      "| Gene Expression | Rationale of Rating | Rating |\n",
      "|-----------------|---------------------|--------|\n",
      "| Is it differentially expressed during disease progression (this is a strong positive sign)? | There is strong evidence that PCSK9 is differentially expressed during the progression of atherosclerosis and is upregulated in response to inflammatory stimuli, which strongly supports the differential expression during disease progression. | Strong - positive (+1) |\n",
      "--------scoring result----------\n",
      "| Drug Development Pipelines Information | Rating | Rationale of Rating |\n",
      "|----------------------------------------|--------|---------------------|\n",
      "| Are there drug development activities and pipelines of pcsk9 for atherosclerosis? (Only consider those pipelines for atherosclerosis) | Neutral (0) | There are small molecule drugs targeting PCSK9 in early clinical development stages (Phase 1 and Phase 2) but none in late-stage clinical trials or approved yet. |\n",
      "--------scoring result----------\n",
      "| Drug Development Pipelines Information | Rating | Rationale of Rating |\n",
      "|----------------------------------------|--------|---------------------|\n",
      "| Are there drug development activities and pipelines of pcsk9 for atherosclerosis? (Only consider those pipelines for atherosclerosis) | Strong negative (-1) | There are approved antibody (Alirocumab, Evolocumab) and siRNA (Inclisiran) drugs for PCSK9 targeting atherosclerosis, suggesting a highly competitive market. |\n",
      "--------scoring result----------\n",
      "### Assayability of PCSK9\n",
      "\n",
      "| Biomarker | Rating           | Rationale of Rating                                                                                 |\n",
      "|-----------|------------------|-----------------------------------------------------------------------------------------------------|\n",
      "| PCSK9     | Weak Positive (+0.5) | Target engagement can be measured non-invasively in plasma through methods like competitive ELISA, but biomarker measurement requires histological tissue staining for atherosclerotic plaque area.|\n",
      "\n",
      "\n",
      "--------scoring result----------\n",
      "  \n",
      "| Data Availability | Rating | Rationale of Rating |\n",
      "|-------------------|--------|---------------------|\n",
      "| - Are there any existing small molecule drugs on pcsk9? - Are crystal structures available? (If yes, then if there is an obvious pocket site?) - Are there tool compounds for pcsk9? | Strong - positive (+1) | There are small molecule drugs targeting PCSK9 in clinical trials or potentially approved, crystal structures available, and tool compounds identified. This signifies a high suitability for small molecule targeting of PCSK9. |\n",
      "--------scoring result----------\n",
      "| Data Availability | Rating | Rationale of Rating |\n",
      "|--------------------|--------|---------------------|\n",
      "| Are there any existing antibodies drugs on pcsk9? <br> Are experimental antibodies available that modulates the target pcsk9? | Strong - positive (+1) | Both Evolocumab and Alirocumab are antibodies targeting PCSK9 that have been approved and are in various stages of ongoing clinical trials. This demonstrates that antibodies targeting PCSK9 are highly suitable and effective. |\n",
      "--------scoring result----------\n",
      "| Unmet Need | Rating | Rationale of Rating |\n",
      "|------------|--------|---------------------|\n",
      "| Unmet Need | Neutral (0) | The target gene PCSK9 has multiple approved drugs including antibodies (Alirocumab, Evolocumab) and siRNA (Inclisiran). However, there are ongoing efforts to develop small molecule inhibitors (e.g., AZD0780, MK-0616) which target the same gene, suggesting there is still interest in better alternatives that might offer benefits in terms of dosing, oral administration, or reduced side effects. However, the market is not in immediate need of a completely new therapeutic given existing approved options. |\n",
      "--------scoring result----------\n",
      "| Tissue Distribution | Rating | Rationale of Rating |\n",
      "|---------------------|--------|---------------------|\n",
      "| Which tissues and organs are the target pcsk9 mainly expressed? Which tissues and organs are the target pcsk9 mainly function? Are there good sirna strategy so far and is the therapeutic direction clear? | Strong - positive (+1) | PCSK9 is highly expressed in the liver and functions primarily to regulate cholesterol metabolism via the LDL receptor. Evidence suggests that siRNA therapies targeting PCSK9 could be effective, such as Inclisiran, which has already shown promise in clinical studies. The therapeutic direction is clear and well-supported by current approaches. |\n",
      "--------scoring result----------\n",
      "| Evidence supporting target gene and disease progression | Rating    | Rationale of Rating                                                                                                        |\n",
      "|---------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------|\n",
      "| Is pcsk9 for atherosclerosis being evaluated on in human, cell or animal perturbation? Any conflict results? |   Strong - positive (+1)         |   Clinical trial evidence including Phase 3 trials and multiple ongoing trials across various drug modalities successfully targeting PCSK9, along with robust in vitro and in vivo data supporting pcsk9's role in atherosclerosis progression. No conflicting results were reported. |\n",
      "--------scoring result----------\n",
      "| Safety-related Information | Rating | Rationale of Rating |\n",
      "|-----------------------------|--------|---------------------|\n",
      "| What is the desired therapeutic effect of pcsk9 for atherosclerosis? Are there any approved drugs targeting pcsk9 for atherosclerosis? If yes, are they generally considered as safe? Are there any animal studies of pcsk9? Are there any side effects in these animal studies? | Strong Positive (+1) | The desired therapeutic effect of targeting PCSK9 for atherosclerosis is to lower LDL cholesterol and reduce the risk of cardiovascular events. There are approved PCSK9 inhibitors (e.g., alirocumab and evolocumab) that are generally considered safe, with predominantly mild to moderate adverse effects. Although there are adverse phenotypes such as microvascular dysfunction in knockout mice, the existing clinical data for PCSK9 inhibitors demonstrate a favorable safety profile in humans.\n",
      "differential_expression_scoring: | Gene Expression | Rationale of Rating | Rating |\n",
      "|-----------------|---------------------|--------|\n",
      "| Is it differentially expressed during disease progression (this is a strong positive sign)? | There is strong evidence that PCSK9 is differentially expressed during the progression of atherosclerosis and is upregulated in response to inflammatory stimuli, which strongly supports the differential expression during disease progression. | Strong - positive (+1) |\n",
      "competitiveness_small_molecule_scoring: | Drug Development Pipelines Information | Rating | Rationale of Rating |\n",
      "|----------------------------------------|--------|---------------------|\n",
      "| Are there drug development activities and pipelines of pcsk9 for atherosclerosis? (Only consider those pipelines for atherosclerosis) | Neutral (0) | There are small molecule drugs targeting PCSK9 in early clinical development stages (Phase 1 and Phase 2) but none in late-stage clinical trials or approved yet. |\n",
      "competitiveness_antibody_or_sirna_scoring: | Drug Development Pipelines Information | Rating | Rationale of Rating |\n",
      "|----------------------------------------|--------|---------------------|\n",
      "| Are there drug development activities and pipelines of pcsk9 for atherosclerosis? (Only consider those pipelines for atherosclerosis) | Strong negative (-1) | There are approved antibody (Alirocumab, Evolocumab) and siRNA (Inclisiran) drugs for PCSK9 targeting atherosclerosis, suggesting a highly competitive market. |\n",
      "assayability_biomarker_scoring: ### Assayability of PCSK9\n",
      "\n",
      "| Biomarker | Rating           | Rationale of Rating                                                                                 |\n",
      "|-----------|------------------|-----------------------------------------------------------------------------------------------------|\n",
      "| PCSK9     | Weak Positive (+0.5) | Target engagement can be measured non-invasively in plasma through methods like competitive ELISA, but biomarker measurement requires histological tissue staining for atherosclerotic plaque area.|\n",
      "\n",
      "\n",
      "small_molecule_scoring:   \n",
      "| Data Availability | Rating | Rationale of Rating |\n",
      "|-------------------|--------|---------------------|\n",
      "| - Are there any existing small molecule drugs on pcsk9? - Are crystal structures available? (If yes, then if there is an obvious pocket site?) - Are there tool compounds for pcsk9? | Strong - positive (+1) | There are small molecule drugs targeting PCSK9 in clinical trials or potentially approved, crystal structures available, and tool compounds identified. This signifies a high suitability for small molecule targeting of PCSK9. |\n",
      "antibody_scoring: | Data Availability | Rating | Rationale of Rating |\n",
      "|--------------------|--------|---------------------|\n",
      "| Are there any existing antibodies drugs on pcsk9? <br> Are experimental antibodies available that modulates the target pcsk9? | Strong - positive (+1) | Both Evolocumab and Alirocumab are antibodies targeting PCSK9 that have been approved and are in various stages of ongoing clinical trials. This demonstrates that antibodies targeting PCSK9 are highly suitable and effective. |\n",
      "unmet_need_scoring: | Unmet Need | Rating | Rationale of Rating |\n",
      "|------------|--------|---------------------|\n",
      "| Unmet Need | Neutral (0) | The target gene PCSK9 has multiple approved drugs including antibodies (Alirocumab, Evolocumab) and siRNA (Inclisiran). However, there are ongoing efforts to develop small molecule inhibitors (e.g., AZD0780, MK-0616) which target the same gene, suggesting there is still interest in better alternatives that might offer benefits in terms of dosing, oral administration, or reduced side effects. However, the market is not in immediate need of a completely new therapeutic given existing approved options. |\n",
      "sirna_scoring: | Tissue Distribution | Rating | Rationale of Rating |\n",
      "|---------------------|--------|---------------------|\n",
      "| Which tissues and organs are the target pcsk9 mainly expressed? Which tissues and organs are the target pcsk9 mainly function? Are there good sirna strategy so far and is the therapeutic direction clear? | Strong - positive (+1) | PCSK9 is highly expressed in the liver and functions primarily to regulate cholesterol metabolism via the LDL receptor. Evidence suggests that siRNA therapies targeting PCSK9 could be effective, such as Inclisiran, which has already shown promise in clinical studies. The therapeutic direction is clear and well-supported by current approaches. |\n",
      "in_vitro_vivo_scoring: | Evidence supporting target gene and disease progression | Rating    | Rationale of Rating                                                                                                        |\n",
      "|---------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------|\n",
      "| Is pcsk9 for atherosclerosis being evaluated on in human, cell or animal perturbation? Any conflict results? |   Strong - positive (+1)         |   Clinical trial evidence including Phase 3 trials and multiple ongoing trials across various drug modalities successfully targeting PCSK9, along with robust in vitro and in vivo data supporting pcsk9's role in atherosclerosis progression. No conflicting results were reported. |\n",
      "assayability_scoring: | Models Availability | Rating    | Rationale of Rating                             |\n",
      "|----------------------|-----------|-----------------------------------------------|\n",
      "| **Models Availability** | **Strong - positive (+1)** | **Both animal and cellular models have been tested with tool compounds for drug discovery.** For example, PCSK9/LDLR binding assays with THP-1-derived macrophages, CRISPR-Cas9 mediated knockout in ApoE-/- mice, PCSK9 immunization in various mouse models, and systemic injection of adenoviral PCSK9 in PCSK9-deficient mice provide extensive data leveraging these models in the context of atherosclerosis. |\n",
      "genetic_evidence_scoring: | Disease Phenotype  | Gene Variant Traits                     | Rating              | Rationale of Rating                                                                                             |\n",
      "|--------------------|-----------------------------------------|---------------------|---------------------------------------------------------------------------------------------------------------|\n",
      "| Atherosclerosis    | Gain-of-function variants of PCSK9 are associated with autosomal dominant hypercholesterolemia, familial hypercholesterolemia, higher LDL-C levels, and increased cardiovascular disease risk, all of which are closely tied to atherosclerosis. Loss-of-function variants are associated with lower LDL-C levels and a reduced risk of atherosclerosis. | Strong - positive (+1) | The evidence consistently demonstrates that PCSK9 variants, both gain and loss of function, significantly influence LDL-C levels and the risk of atherosclerotic cardiovascular disease. The referenced studies provide robust documentation of these associations.                               |\n",
      "moa_scoring: | Molecular Mechanism of the target | Rating | Rationale of Rating |\n",
      "|-----------------------------------|--------|---------------------|\n",
      "| The relatedness of molecular mechanism of PCSK9 with atherosclerosis | Strong - positive (+1) | The molecular mechanisms of PCSK9 directly impact LDL receptor degradation and lipid metabolism, crucial factors in atherosclerosis. Gain-of-function mutations increase LDL cholesterol levels, while loss-of-function mutations decrease them, directly influencing atherosclerosis risk. Additionally, PCSK9 stimulates inflammatory pathways involved in plaque formation and progression. This strong connection makes the rating \"strong-positive (+1)\" valid. |\n",
      "target_safety_scoring: | Safety-related Information | Rating | Rationale of Rating |\n",
      "|-----------------------------|--------|---------------------|\n",
      "| What is the desired therapeutic effect of pcsk9 for atherosclerosis? Are there any approved drugs targeting pcsk9 for atherosclerosis? If yes, are they generally considered as safe? Are there any animal studies of pcsk9? Are there any side effects in these animal studies? | Strong Positive (+1) | The desired therapeutic effect of targeting PCSK9 for atherosclerosis is to lower LDL cholesterol and reduce the risk of cardiovascular events. There are approved PCSK9 inhibitors (e.g., alirocumab and evolocumab) that are generally considered safe, with predominantly mild to moderate adverse effects. Although there are adverse phenotypes such as microvascular dysfunction in knockout mice, the existing clinical data for PCSK9 inhibitors demonstrate a favorable safety profile in humans.\n"
     ]
    }
   ],
   "source": [
    "gene_list = [gene.split('_')[0].lower() for gene in gene_list]\n",
    "for gene in gene_list:\n",
    "    gene = gene.lower().replace(' ', '')\n",
    "    # file_type = 'direct' or 'review' --> 'direct' retrieve reports without review, 'review' retrieve reports with review\n",
    "    run_all_scoring_functions(llm, gene, disease_name, preferred_moa, match_moa = match_moa, file_type= 'direct', no_drug_pipeline_info=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Gather the scoring results to generate the final scoring report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "llmclient=<openai.resources.chat.completions.completions.Completions object at 0x7fd8aa750940> async_client=<openai.resources.chat.completions.completions.AsyncCompletions object at 0x7fd8aa7851f0> root_client=<openai.OpenAI object at 0x7fd888193fa0> root_async_client=<openai.AsyncOpenAI object at 0x7fd8aa7505b0> model_name='gpt-4o-2024-05-13' model_kwargs={} openai_api_key=SecretStr('**********') max_tokens=4096\n",
      "gene_namepcsk9\n",
      "disease_nameatherosclerosis\n",
      "file_typedirect\n",
      "match_moaFalse\n"
     ]
    }
   ],
   "source": [
    "for gene in gene_list:\n",
    "    generate_final_report(llm, gene, disease_name,  file_type = 'direct')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Generated Scoring Report Location\n",
    "\n",
    "The file is stored as:\n",
    "TargetSeek/Target_Scoring_AgentScorer/scoring_result/direct/markdown/{disease_name}/{gene_name}_{disease_name}_scoring.md\n",
    "\n",
    "For example, the scoring report for the gene PCSK9 and the disease atherosclerosis is:\n",
    "TargetSeek/Target_Scoring_AgentScorer/scoring_result/direct/markdown/atherosclerosis/pcsk9_atherosclerosis_scoring.md"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Combine & Save the scoring results as a CSV\n",
    "\n",
    "The next step is to combine all individual gene scoring results into a single CSV file for ranking.\n",
    "\n",
    "This CSV file will contain the scoring results for all genes analyzed for the disease of interest,\n",
    "making it easier to compare and rank the targets systematically. Each row represents a gene with its complete set of scores across all evaluation criteria."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "disease_names = [disease_name]\n",
    "\n",
    "retrieve_path = directory_set_up()\n",
    "\n",
    "for disease_name in disease_names:\n",
    "    # gene_list = load_gene_list(retrieve_path, disease_name)\n",
    "    gene_list = [gene.lower().replace(' ', '').split('_')[0] for gene in gene_list]\n",
    "    ratings_of_genes = {}\n",
    "    for gene in gene_list:\n",
    "        gene = gene.lower().replace(' ', '')\n",
    "        ratings_of_genes[gene] = return_ratings(gene, disease_name, file_type='direct')\n",
    "\n",
    "    ratings_of_genes = map_ratings_to_categories(ratings_of_genes)\n",
    "\n",
    "    store_final_results(ratings_of_genes, disease_name, file_type='tern')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "targetseek_env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
